Fig. 4.

In vivo   anti-IAV activity and safety of PEG_20k–LCVN. (A) The survival curves of mice infected with H3N2 and treated with PEG_20k–LCVN and Ribavirin. Three dose groups of PEG_20k–LCVN were tested and one dose group of Ribavirin was set as positive control. (B) The bodyweight (left), lung values (middle) and NP gene expression (right) of mice. Mice treated with 2 mg/kg/day PEG_20k–LCVN, 75 mg/kg/day Ribavirin or PBS (placebo) were sacrificed on Day 3 post infection (n = 5). NP mRNA level in mice lung was quantified by qPCR. (C) Pathological observations of mice lung stained by H&E, ×200. (D) Mucosa toxicity of PEG_20k–LCVN in vagina of SD rat. PEG_20k–LCVN in PBS was delivered into rat vagina once per day with the dose of 5.0 mg/kg for 7 days to evaluate its stimulation toxicity (H&E staining, 100 µM of each square).